RAPIBLYK offers a new solution for managing fast heart rates in adults with certain heart rhythm disorders, such as atrial fibrillation or atrial flutter. This short-acting medication is designed for temporary use in a hospital setting to help stabilize heart rhythm safely. RAPIBLYK was approved on RAPIBLYK: A New Option for Heart Rate Control in Atrial Arrhythmias Approved on November 22, 2024.
What is the name of the drug, and what does it do?
RAPIBLYK (pronounced rah-PIB-lick) is a beta-1 adrenergic receptor blocker, which means it slows the heart rate by blocking certain signals in the heart. It is especially helpful for conditions like atrial fibrillation or flutter, where the heart rate becomes abnormally fast and needs to be brought under control quickly.
How does it work?
RAPIBLYK works by targeting beta-1 receptors in the heart, reducing the effect of adrenaline and other stress hormones. This action slows the heart rate, allowing the heart to pump blood more effectively and reducing strain on the heart.
What did the research discover?
Clinical studies involving 317 adults with supraventricular tachycardia (a fast heart rhythm originating above the heart’s ventricles) showed that RAPIBLYK effectively slowed the heart rate in most patients. Within 10 minutes of treatment, 40–90% of patients experienced a significant reduction in heart rate, compared to only 0–11% of those who received a placebo. The results demonstrate that RAPIBLYK provides rapid and reliable heart rate control in emergency situations.
What are some of the side effects?
- Hypotension (low blood pressure): The most common side effect, occurring in 9.9% of patients.
Other rare but serious side effects include bradycardia (slow heart rate) and infusion site reactions such as swelling or redness.
What are the dosage recommendations, and how is it prescribed?
RAPIBLYK is administered as an intravenous infusion in a hospital setting, allowing doctors to carefully monitor its effects. The starting dose depends on the patient’s heart condition, with adjustments made every 10–15 minutes as needed. Its short half-life (about 4 minutes) makes it easy to stop the medication quickly if necessary.
Source
AOP Orphan Pharmaceuticals GmbH. Prescribing information for RAPIBLYK (landiolol). November 2024. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf
